Eli Lilly shares are trading higher after the company announced a collaboration with OpenAI to develop medicines for drug-resistant bacteria. Also, Truist Securities reiterated a Buy rating on the stock and raised its price target from $892 to $1000.
Portfolio Pulse from Benzinga Newsdesk
Eli Lilly shares are trading higher following a collaboration announcement with OpenAI to develop medicines for drug-resistant bacteria. Truist Securities reiterated a Buy rating on the stock and raised its price target from $892 to $1000.
June 25, 2024 | 3:10 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Eli Lilly shares are trading higher after announcing a collaboration with OpenAI to develop medicines for drug-resistant bacteria. Additionally, Truist Securities reiterated a Buy rating and raised its price target from $892 to $1000.
The collaboration with OpenAI is a significant development in the pharmaceutical industry, potentially leading to innovative treatments for drug-resistant bacteria. The reiteration of a Buy rating and the increased price target by Truist Securities further boosts investor confidence.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100